Astria Therapeutics, Inc. reports financial results for the first quarter ended 31 March 2023 and provides a corporate update.
“We are excited to be administering STAR-0215 to patients in the Phase 1b/2 ALPHA-STAR clinical trial. We on track to share initial proof-of-concept results which are anticipated in mid-2024,” says Jill C. Milne, Ph.D., CEO at Astria. “We are also encouraged by human mechanistic modeling data that supports the potential for STAR-0215 to be administered once every three or six months for robust suppression of HAE attacks with low treatment burden. The modeling results, in conjunction with our clinical momentum, bring us closer to our goal of making STAR-0215 the first-choice preventative treatment for HAE to help normalize the lives of the HAE community.”
(Source: Astria)
